TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11533267

Group type: EXPERIMENTAL
Intervention: Isoflavone-rich soy (n = 24)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Isoflavone-poor soy (n = 24)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Whey control (n = 21)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: All treatments combined
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Time effect
Number of subjects: 69
Study: 9452150

Group type: EXPERIMENTAL
Intervention: Atrioventricular (AV) delay set at 125 ms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atrioventricular (AV) delay set at 100 ms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atrioventricular (AV) delay set at 75 ms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atrioventricular (AV) delay set at 120 ms (after pacemaker implantation)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atrioventricular (AV) delay set at 100 ms (after pacemaker implantation)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atrioventricular (AV) delay set at 80 ms (after pacemaker implantation)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Reduction in AV delay
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Comparison of invasive and noninvasive protocols
Number of subjects: 12
Study: 7807701

Group type: EXPERIMENTAL
Intervention: Flucytosine (5‐FC) alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Flucytosine (5‐FC) in combination with fluconazole (FLCZ) at half doses
Number of subjects: 60
Study: 2673478

Group type: EXPERIMENTAL
Intervention: S‐adenosyl methionine (SAM)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 591625

Group type: EXPERIMENTAL
Intervention: Oral L-tryptophan (90 mg/kg BW)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31350540

Group type: EXPERIMENTAL
Intervention: N95 respirator usage
Number of subjects: 50

Group type: COMPARATOR
Intervention: No N95 respirator usage
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Near-roadway exposures
Number of subjects: 50
Study: 27164830

Group type: EXPERIMENTAL
Intervention: Human breast milk from preterm infants
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Combined supplementation of preterm infants' BM with choline, ARA, and DHA
Number of subjects: 353
Study: 25654562

Group type: EXPERIMENTAL
Intervention: LUS-implemented diagnosis
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Initial clinical workup
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Chest radiography alone
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Natriuretic peptides
Number of subjects: 1005
Study: 23677794

Group type: EXPERIMENTAL
Intervention: Pharmacist counseling (n=113)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Brief 3-minute drug advice (control; n=161)
Number of subjects: 274
Study: 20921127

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 738
Study: 19953916

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol and remifentanil anesthesia (Group PR)
Number of subjects: 40
Study: 16769493

Group type: EXPERIMENTAL
Intervention: Tooth-tissue-borne Haas-type expanders
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Tooth-borne Hyrax expanders
Number of subjects: 8
Study: 15071125

Group type: EXPERIMENTAL
Intervention: 120 mg of torcetrapib daily
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 120 mg of torcetrapib twice daily
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Torcetrapib
Number of subjects: 19
Study: 11584476

Group type: EXPERIMENTAL
Intervention: Intercessory prayer (IP)
Number of subjects: 219
Study: 9393430

Group type: EXPERIMENTAL
Intervention: Different implant designs
Number of subjects: 2847

Group type: EXPERIMENTAL
Intervention: Implant designs with higher success rates
Number of subjects: 2847

Group type: COMPARATOR
Intervention: Surgeons with less experience
Number of subjects: 2847

Group type: EXPERIMENTAL
Intervention: Specific implant design
Number of subjects: 2847

Group type: EXPERIMENTAL
Intervention: Study sites
Number of subjects: 2847
Study: 8200949

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) low dose (0.4 IU/kg.week)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) high dose (1.2 IU/kg.week)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo (first 6 months)
Number of subjects: 95
Study: 3147809

Group type: EXPERIMENTAL
Intervention: Nifedipine (10, 20, and 30 mg tid)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Propranolol (20, 40, and 80 mg tid)
Number of subjects: 26
Study: 31940865

Group type: EXPERIMENTAL
Intervention: Psychological First Aid (PFA) training
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 129
Study: 28593365

Group type: EXPERIMENTAL
Intervention: Omission of the bladder flap
Number of subjects: 43

Group type: COMPARATOR
Intervention: Bladder flap
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 43
Study: 28742256

Group type: EXPERIMENTAL
Intervention: Hemostatic Sponge with Mastruz (Group SM)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Hemostatic Sponge (Group HS)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Blood Clot (Group BC)
Number of subjects: 36
Study: 25656696

Group type: EXPERIMENTAL
Intervention: Self-support
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Family/friend support
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Health care support
Number of subjects: 317
Study: 24223352

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with lidocaine
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Sprotte needle
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Duration of surgery
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Lithotomy position
Number of subjects: 250
Study: 21905094

Group type: EXPERIMENTAL
Intervention: High dose vitamin B complex
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 17678613

Group type: EXPERIMENTAL
Intervention: Intervention with personal follow-up instructions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intervention with written information only
Number of subjects: 0
Study: 16554289

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg for 3 days followed by ER ciprofloxacin 1000 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: ER ciprofloxacin 1000 mg
Number of subjects: 27
Study: 14653226

Group type: EXPERIMENTAL
Intervention: 15 mg quazepam administered 2 hours after a meal
Number of subjects: 6
Study: 10726786

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 37

Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 37
Study: 8873541

Group type: EXPERIMENTAL
Intervention: Remifentanil at 1.37 ng/ml
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Remifentanil at 32 ng/ml
Number of subjects: 220

Group type: COMPARATOR
Intervention: Isoflurane alone (0 ng/ml remifentanil)
Number of subjects: 220
Study: 7847597

Group type: EXPERIMENTAL
Intervention: Alcohol abuse/dependence
Number of subjects: 144

Group type: COMPARATOR
Intervention: Nonalcoholic depression
Number of subjects: 144
Study: 3132055

Group type: EXPERIMENTAL
Intervention: Nalbuphine 0.2 mg/kg and midazolam 0.05 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Midazolam 0.05 mg/kg alone
Number of subjects: 40
Study: 29224500

Group type: EXPERIMENTAL
Intervention: Warm clothing
Number of subjects: 9

Group type: COMPARATOR
Intervention: Limited clothing
Number of subjects: 9
Study: 28114981

Group type: EXPERIMENTAL
Intervention: Telephone
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Mail/Postal
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Email
Number of subjects: 687
Study: 24820476

Group type: COMPARATOR
Intervention: Laser acupuncture (Pointer Pulse, 650 nm, 5 mW, 120 s per acupoint)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Laser acupuncture
Number of subjects: 26
Study: 23328189

Group type: EXPERIMENTAL
Intervention: Olmesartan (ARB)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study: 21337043

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) - two injections of 1.25 mg IVB 6 weeks apart
Number of subjects: 81

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB)
Number of subjects: 81
Study: 19351299

Group type: EXPERIMENTAL
Intervention: Healthy Living Course (HLC) program
Number of subjects: 185
Study: 16977739

Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg/day
Number of subjects: 6500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6500

Group type: EXPERIMENTAL
Intervention: Rimonabant
Number of subjects: 6500
Study: 12612157

Group type: EXPERIMENTAL
Intervention: TOP/beta-glucan treatment (1.8 g TOP and 2.8 g beta-glucan/d)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control foods (similar to treatment but without TOP and beta-glucan)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: TOP/beta-glucan treatment
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control foods
Number of subjects: 112
Study: 10960369

Group type: EXPERIMENTAL
Intervention: CPAP at 10 cm H(2)O during CPB
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (lungs open to the atmosphere during CPB)
Number of subjects: 14
Study: 7597300

Group type: EXPERIMENTAL
Intervention: Excision of primary melanoma with up to 2-mm thickness and 1-cm margins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Narrow excision for melanoma thicker than 2 mm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Excision of primary tumor
Number of subjects: 0
Study: 2253088

Group type: EXPERIMENTAL
Intervention: Natamycin (Tymasil)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7313578

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) administration of ampicillin
Number of subjects: 44

Group type: COMPARATOR
Intervention: Intravenous (IV) administration of ampicillin
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both IM and IV administration of ampicillin
Number of subjects: 44
Study: 31568281

Group type: EXPERIMENTAL
Intervention: Preoperative magnetic resonance imaging for flap tissue planning
Number of subjects: 62

Group type: COMPARATOR
Intervention: External Doppler ultrasonography for flap planning
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Preoperative vascular mapping by magnetic resonance imaging
Number of subjects: 62

Group type: COMPARATOR
Intervention: External Doppler ultrasonography
Number of subjects: 62
Study: 28434473

Group type: EXPERIMENTAL
Intervention: Acupressure at LIV3
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Acupressure at LI4
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo acupressure
Number of subjects: 97
Study: 25828037

Group type: EXPERIMENTAL
Intervention: Small particle hyaluronic acid plus lidocaine (SPHAL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 23512273

Group type: EXPERIMENTAL
Intervention: Group psychotherapy intervention for body image-related concerns
Number of subjects: 150
Study: 21163921

Group type: EXPERIMENTAL
Intervention: Variants in STXBP5 (rs1039084)
Number of subjects: 1366

Group type: EXPERIMENTAL
Intervention: Variants in VWF (rs1063856)
Number of subjects: 1366

Group type: COMPARATOR
Intervention: Variants in SCARA5, STAB2, STX2, TC2N, and CLEC4M
Number of subjects: 1366
Study: 19489429

Group type: EXPERIMENTAL
Intervention: Individual reminiscence therapy (5-6 weekly sessions, 30-60 minutes each)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 80
Study: 17823443

Group type: COMPARATOR
Intervention: Basal diet (54% carbohydrate, 16% protein, 30% fat, 7% saturated fat)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Moderate-carbohydrate diet (39%)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate (26%) and low-saturated-fat (9%) diet
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate (26%) and high-saturated-fat (15%) diet
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Acute weight loss diet (−1103.0 ± 216.5 kcal/d)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Stabilization at reduced weight
Number of subjects: 131
Study: 15483468

Group type: COMPARATOR
Intervention: Recombinant gp120 HIV vaccine (AIDSVAX B/B)
Number of subjects: 5417
Study: 11213870

Group type: EXPERIMENTAL
Intervention: Abalon (soy protein [50 g/day] with high levels of isoflavones [minimum 165 mg/day] and cotyledon fiber [20 g/day])
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (casein [50 g/day] and cellulose [20 g/day])
Number of subjects: 20
Study: 9669254

Group type: EXPERIMENTAL
Intervention: Palmaz‐Schatz stent implantation
Number of subjects: 110

Group type: COMPARATOR
Intervention: PTCA (balloon angioplasty)
Number of subjects: 110
Study: 8675565

Group type: EXPERIMENTAL
Intervention: SMS (1 microgram/kg, sc) + GHRH (1 microgram/kg, iv)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control test (no SMS) + GHRH (1 microgram/kg, iv)
Number of subjects: 24
Study: 2802549

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (1,000 mg single dose)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Cefaclor (250 mg three times a day for 7 days)
Number of subjects: 89
Study: 768913

Group type: EXPERIMENTAL
Intervention: Acebutolol (600 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study: 28723821

Group type: EXPERIMENTAL
Intervention: Balance wristband
Number of subjects: 179

Group type: COMPARATOR
Intervention: Defective wristband
Number of subjects: 179

Group type: COMPARATOR
Intervention: No wristband
Number of subjects: 179
Study: 31052277

Group type: COMPARATOR
Intervention: Permissive underfeeding
Number of subjects: 91

Group type: COMPARATOR
Intervention: Intensive insulin therapy (IIT)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Caloric intake
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Baseline SOFA score and platelets
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 91
Study: 28381506

Group type: EXPERIMENTAL
Intervention: IV immunoglobulin (IVIg) administered IV at doses of 0.2 or 0.4 g/kg every 2 weeks for 18 months
Number of subjects: 390

Group type: COMPARATOR
Intervention: Placebo (low‐dose albumin)
Number of subjects: 390
Study: 26115520

Group type: EXPERIMENTAL
Intervention: Conventional liver transplantation with venovenous bypass
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Piggyback liver transplantation
Number of subjects: 32
Study: 23527597

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 315

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 315
Study: 21450935

Group type: EXPERIMENTAL
Intervention: Obese subjects
Number of subjects: 471

Group type: COMPARATOR
Intervention: Normal-weight subjects (BMI < 25)
Number of subjects: 471
Study: 19366272

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg/day (with option to adjust to 5 or 10 mg/day at weeks 4 and 8)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg/day
Number of subjects: 116

Group type: COMPARATOR
Intervention: Tolterodine ER 4 mg/day (pre-washout)
Number of subjects: 116

Group type: COMPARATOR
Intervention: No drug (post-washout)
Number of subjects: 116
Study: 16393433

Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg twice daily for 5 days
Number of subjects: 118

Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 118
Study: 14705151

Group type: EXPERIMENTAL
Intervention: Higher risk and higher motivated group
Number of subjects: 78

Group type: COMPARATOR
Intervention: Combined group
Number of subjects: 78

Group type: COMPARATOR
Intervention: Lower risk or lower motivated group
Number of subjects: 78
Study: 11072552

Group type: EXPERIMENTAL
Intervention: Backrest elevation of 30 degrees
Number of subjects: 8

Group type: COMPARATOR
Intervention: Flat/horizontal backrest position
Number of subjects: 8
Study: 9069297

Group type: EXPERIMENTAL
Intervention: Sucralfate plus antacid, diphenhydramine, and viscous lidocaine
Number of subjects: 111

Group type: COMPARATOR
Intervention: Standard combination of antacid, diphenhydramine, and viscous lidocaine
Number of subjects: 111
Study: 8366411

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate potassium for 10 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: No antibiotic
Number of subjects: 15
Study: 2951813

Group type: EXPERIMENTAL
Intervention: Duovent
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31934945

Group type: EXPERIMENTAL
Intervention: Continuous nurse assignment on the last 2 days of hospitalization
Number of subjects: 18203
Study: 30010081

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMFs) treatment (50 min/session, 6 sessions/week, total of 25 sessions)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sham PEMFs (control group)
Number of subjects: 43
Study: 27764835

Group type: EXPERIMENTAL
Intervention: Verbal empathy and touch
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Verbal empathy
Number of subjects: 267

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 267
Study: 25092690

Group type: EXPERIMENTAL
Intervention: Nemonoxacin 250 mg
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Nemonoxacin 500 mg
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Nemonoxacin 750 mg
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Nemonoxacin (250 to 750 mg)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Nemonoxacin (maximum dose 1,250 mg)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Nemonoxacin
Number of subjects: 92
Study: 22701296

Group type: EXPERIMENTAL
Intervention: Living in Harmony program (LIH, an 8 lesson cognitive‐behaviorally based program)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Educational‐Support program (ES, an 8 lesson education program)
Number of subjects: 47
Study: 19531688

Group type: EXPERIMENTAL
Intervention: Walking intervention (30 min, 5 days a week, for 6 weeks)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Social visits (control group, same frequency as walking intervention)
Number of subjects: 97
Study: 18478914

Group type: EXPERIMENTAL
Intervention: Conventional therapy + NPPV
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 32
Study: 15157952

Group type: EXPERIMENTAL
Intervention: Nocturnal plasma levels of interleukin‐6 (IL‐6)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Nocturnal plasma levels of tumor necrosis factor‐alpha (TNF)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Pre-sleep IL‐6 levels at 23:00 h
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: IL‐6 levels at 03:00 h
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Polysomnography and blood sampling
Number of subjects: 31
Study: 11167475

Group type: EXPERIMENTAL
Intervention: Inflating cuffs with 40% nitrous oxide gas mixture
Number of subjects: 75
Study: 9591438

Group type: EXPERIMENTAL
Intervention: Eosinophil cationic protein (ECP) evaluation before, during, and after immunotherapy with pollen or mite allergens (Allergovit or Novo‐Helisen, Nexter, Allergopharma)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Serum total IgE levels
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: ECP levels during immunotherapy
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (children without allergic hypersensitivity)
Number of subjects: 111
Study: 7887824

Group type: EXPERIMENTAL
Intervention: 2-hour hemodialysis at high blood flow (400 ml/min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 4-hour hemodialysis at low blood flow (200 ml/min)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High urea elimination during hemodialysis
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ultrafiltration volume
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Urea removal and ultrafiltration between dialyses
Number of subjects: 20
Study: 3348136

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) oral spray
Number of subjects: 9

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN) sublingual tablets
Number of subjects: 9
Study: 6105567

Group type: EXPERIMENTAL
Intervention: Pentagastrin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 150
Study: 31058709

Group type: EXPERIMENTAL
Intervention: Berkeley Rudimentary Vision Test (BRVT)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Freiburg Acuity Test (FrACT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comparison of BRVT and FrACT
Number of subjects: 50
Study: 28678044

Group type: EXPERIMENTAL
Intervention: Screening for gastrointestinal risk factors and prophylactic proton pump inhibitor (PPI) therapy (pantoprazole 40 mg for 1 year)
Number of subjects: 2009

Group type: COMPARATOR
Intervention: Control group (no screening or PPI therapy)
Number of subjects: 2009
Study: 26431854

Group type: EXPERIMENTAL
Intervention: TII SCB (16 mL of lidocaine 1.5% with epinephrine 5 µg·mL(‐1) into the largest neural cluster and additional 16 mL divided into equal aliquots injected inside each satellite cluster)
Number of subjects: 40

Group type: COMPARATOR
Intervention: AXB (5.5 mL around the musculocutaneous nerve and 23.5 mL at the 6 o'clock position of the axillary artery)
Number of subjects: 40
Study: 23719518

Group type: EXPERIMENTAL
Intervention: Unilateral passive accessory mobilization to the symptomatic hand
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nontherapeutic dose of intermittent ultrasound on the affected side
Number of subjects: 28
Study: 20692708

Group type: EXPERIMENTAL
Intervention: Self-directedness
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Asceticism
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Borderline personality disorder symptoms
Number of subjects: 134
Study: 19237882

Group type: EXPERIMENTAL
Intervention: Vasopressin (0.01-0.03 units/min)
Number of subjects: 779

Group type: COMPARATOR
Intervention: Norepinephrine (5-15 microg/min)
Number of subjects: 779

Group type: EXPERIMENTAL
Intervention: Vasopressin infusion
Number of subjects: 779

Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 779